読み込み中
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
前日終値
$8.84
+$0.23 · +2.67%
日中の時刻はETです。市場データは遅延する場合があります。
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
日中レンジ
現在 $8.84
52週レンジ
現在 $8.84
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
47
適正価値
センチメント
54
まちまち
リスク
47
やや高いリスク
モメンタム
37
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
日中レンジ
現在 $8.84
52週レンジ
現在 $8.84
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 968.4万 USD | 1.35億 USD | 9137万 USD | 5390.5万 USD | 2.01億 USD |
| 売上原価 | 370.2万 USD | — | — | — | — |
| 粗利益 | 598.2万 USD | 1.35億 USD | 9137万 USD | 5390.5万 USD | 2.01億 USD |
| 研究開発 | 1.35億 USD | 2.23億 USD | 2.21億 USD | 1.36億 USD | 8228.4万 USD |
| 販売・一般管理 | 5939.2万 USD | 6719.9万 USD | 6183.5万 USD | 4990万 USD | 4631.8万 USD |
| 営業費用 | 1.91億 USD | 2.9億 USD | 2.82億 USD | 1.85億 USD | 1.29億 USD |
| 受取利息 | 1413.9万 USD | 2581.6万 USD | 3101.4万 USD | 634.9万 USD | 4.2万 USD |
| 減価償却費と償却費 | 89.5万 USD | 89.3万 USD | 92.8万 USD | 74.4万 USD | 111.5万 USD |
| 営業利益 | −1.85億 USD | −1.55億 USD | −1.91億 USD | −1.32億 USD | 7197.5万 USD |
| 純利益 | −2.44億 USD | −1.22億 USD | −1.47億 USD | −1.17億 USD | 6697.5万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$30.00
上昇余地（239.37%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM980.75万0.01%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI789.02万0.08%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF458.34万0.00%954億 USD0.05%$235+0.80%
Dimensional - US Small Cap ETFDFAS316.97万0.01%338.69億 USD0.31%$78.35+0.32%
iShares Biotechnology ETFIBB299.3万0.03%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO238.57万0.01%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO201.2万0.01%139.17億 USD0.24%$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA184.88万0.01%218.24億 USD0.03%$32.79+0.40%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
